In Brief: Roche Soriatane
Executive Summary
Roche Soriatane: Teratogenicity and labeling issues regarding Soriatiane (acitretin) as treatment for severe psoriasis will be discussed at April 17 meeting of FDA's Dermatologic & Ophthalmic Drugs Advisory Committee. The committee also will meet April 18 in closed session. Both days will begin at 8:30 a.m. at the Holiday Inn in Gaithersburg, Md...